Drug Trial Radar · NCT01289990
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jul 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,705
Actual
Start
Feb 2011
Primary completion
May 2013
Study completion May 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Feb 4, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
Conditions
- Diabetes Mellitus, Type 2
Interventions
BI 10773Drug
BI 10773 tablets once daily
PlaceboDrug
Placebo matching BI 10773 low dose
PlaceboDrug
Placebo matching BI 10773 high dose
PlaceboDrug
Placebo matching Sitagliptin
PlaceboDrug
Placebo matching BI 10773 high dose
PlaceboDrug
Placebo matching BI 10773 high dose
BI 10773Drug
BI 10773 tablets once daily
PlaceboDrug
Placebo matching BI 10773 low dose
PlaceboDrug
Placebo matching BI 10773 low dose
BI 10773Drug
BI 10773 tablets once daily
PlaceboDrug
Placebo matching BI 10773 low dose
PlaceboDrug
Placebo matching BI 10773 high dose
PlaceboDrug
Placebo matching Sitagliptin
BI 10773Drug
BI 10773 tablets once daily
BI 10773Drug
BI 10773 tablets once daily
BI 10773Drug
BI 10773 tablets once daily
PlaceboDrug
Placebo matching BI 10773 high dose
BI 10773Drug
BI 10773 tablets once daily
PlaceboDrug
Placebo matching BI 10773 low dose
PlaceboDrug
Placebo matching BI 10773 high dose
PlaceboDrug
Placebo matching Sitagliptin
Sitagliptin 100mgDrug
Sitagliptin once daily
BI 10773Drug
BI 10773 tablets once daily
PlaceboDrug
Placebo matching BI 10773 low dose
PlaceboDrug
Placebo matching BI 10773 low dose
PlaceboDrug
Placebo matching BI 10773 low dose
PlaceboDrug
Placebo matching BI 10773 high dose
PlaceboDrug
Placebo matching BI 10773 low dose
PlaceboDrug
Placebo matching BI 10773 high dose
PlaceboDrug
Placebo matching BI 10773 high dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of TreatmentTime frame: Baseline and 52 weeks
- Changes From Baseline in HbA1c (%) After 76 Weeks of TreatmentTime frame: Baseline and 76 weeks
Locations
243 sites in 19 countries. Site status is shown where the registry gives one.
1245.31.10145 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1245.31.10162 Boehringer Ingelheim Investigational Site
Glendale, Arizona
1245.31.10124 Boehringer Ingelheim Investigational Site
Mesa, Arizona
1245.31.10108 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
1245.31.10046 Boehringer Ingelheim Investigational Site
Tempe, Arizona
1245.31.10154 Boehringer Ingelheim Investigational Site
Chino, California
1245.31.10149 Boehringer Ingelheim Investigational Site
Rancho Cucamonga, California
1245.31.10131 Boehringer Ingelheim Investigational Site
West Hills, California
1245.31.10038 Boehringer Ingelheim Investigational Site
Northglenn, Colorado
1245.31.10127 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut
1245.31.10137 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1245.31.10133 Boehringer Ingelheim Investigational Site
Jupiter, Florida
1245.31.10006 Boehringer Ingelheim Investigational Site
Miami, Florida
1245.31.10085 Boehringer Ingelheim Investigational Site
Plantation, Florida
1245.31.10080 Boehringer Ingelheim Investigational Site
Decatur, Georgia
1245.31.10077 Boehringer Ingelheim Investigational Site
Perry, Georgia
1245.31.10001 Boehringer Ingelheim Investigational Site
Chicago, Illinois
1245.31.10159 Boehringer Ingelheim Investigational Site
Des Moines, Iowa
1245.31.10014 Boehringer Ingelheim Investigational Site
Dubuque, Iowa
1245.31.10117 Boehringer Ingelheim Investigational Site
Arkansas City, Kansas
1245.31.10157 Boehringer Ingelheim Investigational Site
Newton, Kansas
1245.31.10146 Boehringer Ingelheim Investigational Site
Louisville, Kentucky
1245.31.10003 Boehringer Ingelheim Investigational Site
Dearborn, Michigan
1245.31.10059 Boehringer Ingelheim Investigational Site
New Hyde Park, New York
1245.31.10034 Boehringer Ingelheim Investigational Site
Rochester, New York
1245.31.10123 Boehringer Ingelheim Investigational Site
Smithtown, New York
1245.31.10071 Boehringer Ingelheim Investigational Site
Asheboro, North Carolina
1245.31.10086 Boehringer Ingelheim Investigational Site
Salisbury, North Carolina
1245.31.10129 Boehringer Ingelheim Investigational Site
Carlisle, Ohio
1245.31.10045 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1245.31.10119 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1245.31.10130 Boehringer Ingelheim Investigational Site
Gallipolis, Ohio
1245.31.10158 Boehringer Ingelheim Investigational Site
Mt. Pleasant, South Carolina
1245.31.10015 Boehringer Ingelheim Investigational Site
Simpsonville, South Carolina
1245.31.10033 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee
1245.31.10112 Boehringer Ingelheim Investigational Site
Memphis, Tennessee
1245.31.10156 Boehringer Ingelheim Investigational Site
Houston, Texas
1245.31.10151 Boehringer Ingelheim Investigational Site
Hurst, Texas
1245.31.10143 Boehringer Ingelheim Investigational Site
Killeen, Texas
1245.31.10155 Boehringer Ingelheim Investigational Site
San Antonio, Texas
Showing 40 of 243 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.